Alex Bastian Joins Memo Therapeutics AG as VP of Commercial Strategy
Memo Therapeutics AG (MTx), an innovative late-stage biotech firm focused on transforming unique human immune responses into treatments for viral infections and cancer, has announced the strategic appointment of Alex Bastian as its new Vice President of Commercial Strategy.
Alex Bastian's Professional Experience
Alex Bastian comes to Memo Therapeutics AG with extensive experience in the biotech industry. He is a well-respected commercial leader, having most recently worked as the VP of Commercial & Patient Access at AM-Pharma, where he successfully spearheaded market access initiatives for a groundbreaking in-hospital therapy designed to treat acute kidney injury.
Prior to his role at AM-Pharma, Bastian served as VP and Head of Value & Market Access at Galapagos. In this capacity, he established a global function dedicated to market access, health economics, and policy, which played a pivotal role in launching a product in a highly competitive therapeutic area. His track record demonstrates his ability to navigate complex markets and deliver measurable outcomes.
Importance of the Appointment
Erik van den Berg, CEO of MTx, expressed his excitement about Bastian's arrival, stating, "Alex joins us at an exciting time as we move toward initiating a Phase III trial in kidney transplant patients with BK virus infection ahead of our commercial launch. We are thrilled to enhance our in-house expertise with such a high-caliber individual, and on behalf of the senior leadership team, I extend a warm welcome to Alex." This enthusiasm highlights the strategic importance of his role as MTx gears up to advance its product into critical development phases.
In light of his new role, Alex Bastian shared his confidence in MTx's capabilities, stating, "With a best and first-in-class antibody for BK viremia, MTx provides new hope for patients who currently have no effective treatment options. I am eager to join a company with such a promising asset and a powerful technology platform, and I look forward to collaborating with the team." His dedication to MTx's mission is evident, setting a positive tone for future initiatives.
Recent Developments at Memo Therapeutics AG
Alongside strengthening its leadership team, Memo Therapeutics AG has recently achieved a successful capital raise of CHF 20 million in May, attracting new investors such as Ysios Capital and Kurma Partners. This brings the total funding for its Series C round to CHF 45 million. These funds are aimed at accelerating the development of Potravitug, the company’s lead candidate, which is poised to make significant advancements in kidney transplant therapies.
Additionally, in July, MTx announced the appointment of Paul Carter as Chairperson of the Board of Directors, a move that enhances the company's governance with significant experience. Carter brings over a decade of commercial experience in virology from his time at Gilead Sciences, making him a valuable asset to the MTx team.
About Memo Therapeutics AG and Its Innovations
Memo Therapeutics AG is dedicated to developing advanced antibody therapies aimed at treating viral infections and cancer. Its lead program, Potravitug, is currently in Phase II development and specifically targets BK viremia in kidney transplant recipients. This condition presents a major challenge, as it can lead to reduced kidney functionality and significantly impact patient survival rates. The therapeutic potential of Potravitug could transform treatment options and address a market potential exceeding $1 billion.
Alongside Potravitug, MTx is also committed to identifying novel oncology targets, utilizing both independent research and strategic partnerships. Notably, the company has partnered with Ono Pharmaceutical, reinforcing its dedication to advancing innovative therapies.
At the core of MTx’s innovative approach is its proprietary DROPZYLLA technology. This advanced antibody repertoire copying engine features high-throughput screening capabilities, which are essential for developing effective treatments. MTx operates from Schlieren / Zurich and enjoys strong support from several esteemed investors, including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, and Vesalius Biocapital.
Frequently Asked Questions
What is the role of Alex Bastian at Memo Therapeutics AG?
Alex Bastian has joined Memo Therapeutics AG as the Vice President of Commercial Strategy, focusing on market access and commercialization strategies for the company's products.
What is Potravitug?
Potravitug is Memo Therapeutics AG's lead candidate, currently in Phase II development, targeting BK viremia in kidney transplant recipients, a condition that can severely affect kidney functionality.
Why is Alex Bastian's appointment significant?
His appointment is significant as he brings extensive experience in market access and commercial strategy, which is crucial for MTx's upcoming Phase III trial and potential product launch.
What funding has Memo Therapeutics AG recently secured?
In May, Memo Therapeutics AG secured CHF 20 million in additional funding, increasing its Series C financing to CHF 45 million, enhancing resources for its ongoing projects.
What partnerships does Memo Therapeutics AG have?
Memo Therapeutics AG maintains a partnership with Ono Pharmaceutical, aimed at advancing the development of innovative treatments in oncology and other areas.
